Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells

Eltombopag：对正常和再生障碍性贫血造血干细胞的新作用模式

• 批准号: 10676888
• 负责人: Babal K Jha
• 金额: $ 65.88万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-15 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10676888
• 关键词: Affect; Aftercare; Agonist; Aplastic Anemia; Ascorbic Acid; Binding; Biochemical; Biological; Biological Models; Blood Cells; Bone marrow failure; CD34 gene; Catalytic Domain; Cell Line; Cell Lineage; Cells; Chemicals; Clinical; Clinical Data; Clinical Research; Coupled; Cryoelectron Microscopy; Crystallography; DNA; DNA methylation profiling; Dependence; Dioxygenases; Elderly; Engraftment; Enhancers; Enzymes; Epigenetic Process; Failure; Gene Expression Profile; Gene Mutation; Genes; Hematology; Hematopoiesis; Hematopoietic; Hematopoietic stem cells; Human; Hypermethylation; Immune; Immune mediated destruction; In Vitro; In complete remission; Individual; Iron; Iron Chelating Agents; Iron Chelation; Kinetics; MPL gene; Mediating; Modeling; Molecular; Mus; Myelogenous; Neoplasms; Pathway interactions; Patients; Peptides; Pharmaceutical Preparations; Platelet Count measurement; Population; Production; Proliferating; Property; Proteins; RNA; Radiation; Recovery; Refractory; Relapse; Residual state; Resolution; Role; Signal Transduction; Somatic Mutation; System; Testing; Therapeutic; Therapeutic immunosuppression; Thrombocytopenic Purpura; alpha ketoglutarate; analog; base; bone marrow failure syndrome; clinically relevant; cofactor; demethylation; design; epigenetic regulation; extracellular; hematopoietic stem cell expansion; high throughput screening; improved; in vivo; in vivo Model; inhibitor; leukemia; loss of function mutation; mRNA Expression; mimetics; mouse model; novel; polypeptide; promoter; receptor-mediated signaling; response; small molecule; stem cells; success; transcriptome sequencing

Summary Idiopathic aplastic anemia (AA) is characterized by immune-mediated hematopoietic stem and progenitor cells (HSPCs) destruction resulting in deficiencies across all hematopoietic lineages and bone marrow failure. Despite of the therapeutic successes of immunosuppressive therapies (IST), approximately one third of patients remain refractory and many of the responses are incomplete. Recently, a synthetic thrombopoietin receptor (TPOR) agonist, Epag has been shown to be effective in AA. In addition to the anticipated effect on platelet counts, Epag also produced remarkable tri-lineage hematopoiesis. These effects expanded the indication spectrum of Epag from immune thrombocytopenic purpura to AA, establishing this drug as an essential hematologic therapeutic. Recent studies demonstrate that Epag’s hematopoietic activity is also observed in murine models despite the lack of binding to murine TpoR. We confirmed similar effects in murine cells where Epag treatment remarkably expanded HSCs without any effect on the TpoR signaling. These observations suggested that a significant part of Epag’s activities are TPOR independent, in contrast to peptide TPO analogs, e.g., romiplostin. These TPOR independent effects of Epag were hypothesized to be due to its iron chelating properties, but the molecular mechanism as to how this iron-binding could drive the HSPCs expansion remains speculative. Epag effects on intracellular iron may affect certain iron-dependent epigenetic pathway/s that promote HSPCs self-replication. For instance, TET-dioxygenases (TET1-3) are Fe2+- and α- ketoglutarate (αKG) dependent DNA-dioxygenases, which mediate CpG demethylation of promoters and enhancers in HSPCs. Consequently, by changing gene expression patterns, TETs control HSPCs expansion and differentiation. TET2 is the most abundant TET-dioxygenase in HSPCs, and somatic loss-of-function (LOF) mutations of this gene frequently occur in myeloid neoplasia and clonal hematopoiesis of indeterminate potential (CHIP), a prodromal condition in otherwise healthy elderly individuals characterized by high progression rate to a frank leukemia. Our proposal is designed to determine the effects of Epag on normal hematopoiesis mediated by its ability to inhibit TET-activity. Based on our analysis of clinical data coupled with biochemical analysis we hypothesize that, Epag-mediated TET- inhibition is responsible for tri-lineage response in AA via HSC expansion and on the biochemical level decreased 5hmC content leading to hypermethylation as a result of direct inhibition of TET2. Our current proposal will provide a proof of concept for the reversible transient TET-inhibition as a basis for HSC expansion that may restore normal hematopoiesis.

总结